Maria Stella Figueiredo

@sp.unifesp.br

HEMATOLOGY AND BLOOD TRANSFUSION DIVISION / DEPARTMENT OF CLINICAL AND EXPERIMENTAL ONCOLOGY
ESCOLA PAULISTA DE MEDICINA - UNIVERSIDADE FEDERAL DE SÃO PAULO



                 

https://researchid.co/msfigueiredo

RESEARCH, TEACHING, or OTHER INTERESTS

Hematology, Molecular Biology

124

Scopus Publications

664

Scholar Citations

10

Scholar h-index

10

Scholar i10-index

Scopus Publications

  • Patient Blood Management in Cardiovascular Surgery
    Isabel Cristina Céspedes, Maria Stella Figueiredo, Antonio Alceu Dos Santos and Nelson A Hossne


  • Health-care transition services for sickle cell disease in Brazil
    Jane S Hankins, Clarisse Lobo, Josefina A P Braga, Tarun Aurora, Kelly Pimenta, Maria Stella Figueiredo, and Ana A Baumann
    Elsevier BV

  • Blood concentrations of α-Klotho and FGF-23 exhibit no correlation with bone mineral density in elderly individuals
    Karina Moura Sawada, Niele Silva de Moraes, Lara Miguel Quirino Araújo, Fernanda Martins Gazoni, Marise Lazaretti-Castro, Maysa Seabra Cendoroglo, John P. Bilezikian, Maria Stella Figueiredo, and Fania Cristina dos Santos
    Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
    OBJECTIVE To investigating the relationship between α-Klotho and FGF-23 with bone biochemical markers and bone density findings in extremely aged individuals. METHODS A total of 55 individuals with a mean age of 85.6 years were subjected to clinical, biochemical, and bone mineral density analyses and the enzyme-linked immunosorbent assay-based detection of α-Klotho and FGF-23. The mean, standard deviation, median, and interquartile ranges of the sample values were determined, and Spearman's test for association assessments was used for statistical analysis. RESULTS The study participants expressed median FGF-23 and α-Klotho levels of 69.81 RU/mL (51.43 RU/mL) and 733.43 pg/mL (360.83 pg/mL), respectively. The majority of the participants possessed osteopenia (54.5%) and a vitamin D deficiency (57%). The 25-hydroxyvitamin D concentrations ranged between 7.1 and 47.5ng/mL, with a median of 18.1ng/mL. CONCLUSION No substantial associations were discovered between α-Klotho and FGF-23 levels and bone density in the study participants.

  • Patient Blood Management Program Implementation: Comprehensive Recommendations and Practical Strategies
    Isabel Cristina Céspedes, Maria Stella Figueiredo, Nelson A Hossne, I. Suriano, Rita de Cássia Rodrigues, M. Barros, Manoel Antonio de Paiva, Fernanda Chohfi Atallah, Bárbara Burza Benini, Adriano Miziara Gonzalez,et al.

    Introduction Blood transfusion is one of the most common medical practices worldwide. However, current scientific literature has shown that the immunomodulatory effects of blood transfusion are associated with an increased likelihood of infection, prolonged hospitalization, and morbimortality. Also, it means high costs for healthcare systems. Methods In this context, acknowledging that blood transfusions are essentially heterologous cell transplantations, the use of therapeutic options has gained strength and is collectively known as the patient blood management (PBM) program. PBM is an approach based on three main pillars: (1) treating anemias and coagulopathies in an optimized manner, especially in the preoperative period; (2) optimizing perioperative hemostasis and the use of blood recovery systems to avoid the loss of the patient's blood; (3) anemia tolerance, with improved oxygen delivery and reduced oxygen demand, particularly in the postoperative period. Results Current scientific evidence supports the effectiveness of PBM by reducing the need for blood transfusions, decreasing associated complications, and promoting more efficient and safer blood management. Thus, PBM not only improves clinical outcomes for patients but also contributes to the economic sustainability of healthcare systems. Conclusion The aim of this review was to summarize PBM strategies in a comprehensive, evidence-based approach through a systematic and structured model for PBM implementation in tertiary hospitals. The recommendations proposed herein are from researchers and experts of a high-complexity university hospital in the network of the Sistema Único de Saúde, presenting itself as a strategy that can be followed as a guideline for PBM implementation in other settings.

  • Sickle Cell Disease in Brazil: Current Management
    Aderson da Silva Araújo, Ana Cristina Silva Pinto, Clarisse Lopes de Castro Lobo, Maria Stella Figueiredo, Sandra Fátima Menosi Gualandro, Sara Teresinha Olalla Saad, and Rodolfo Delfini Cançado
    Informa UK Limited
    Sickle cell disease (SCD) comprises inherited red blood cell disorders due to a mutation in the β-globin gene (c20A > T, pGlu6Val) and is characterized by the presence of abnormal hemoglobin, hemoglobin S, hemolysis, and vaso-occlusion. This mutation, either in a homozygous configuration or in compound states with other β-globin mutations, leads to polymerization of hemoglobin S in deoxygenated conditions, causing modifications in red blood cell shape, particularly sickling. Vaso-occlusive crisis (VOC) is the hallmark of the disease, but other severe complications may arise from repeated bouts of VOCs. SCD is considered a global health problem, and its incidence has increased in some areas of the world, particularly the Americas and Africa. Management of the disease varies according to the region of the world, mainly due to local resources and socioeconomic status. This review aimed to describe more recent data on SCD regarding available treatment options, especially in Brazil. New treatment options are expected to be available to all patients, particularly crizanlizumab, which is already approved in the country.

  • Consensus of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) and the Brazilian Ministry of Health - General management of blood and blood products on the tests necessary for the release of exceptional medicines for sickle cell disease
    Clarisse Lobo, Aderson Araújo, Alexandre de Albuquerque Antunes, Ana Cristina Silva Pinto, Ariadne Carvalho Godinho, Cassia Silvestre Mariano Pires, Cinthia Cristina Matheus, Xerez de Albuquerque, Daniele Campos Fontes Neves, Fábio de Lima Moreno,et al.
    Elsevier BV

  • Vertebral fractures and low lean mass in young men with sickle cell disease: Lack of association with bone mineral density and clinical characteristics
    Pedro Paulo de Alcantara Pedro, Charlles Heldan de Moura Castro, Marcelo de Medeiros Pinheiro, Lucila Macedo Gonçalves, Maria Stella Figueiredo, and Vera Lúcia Szejnfeld
    Wiley
    Low bone mass, osteoporosis and

  • Factors related to the readiness of Brazilian chronic pediatric patients to transition to care in adult clinics
    Fernanda Souza Angotti Carrara, Daniela Gerent Petry Piotto, Ilana Izidoro Silva, Claudio Arnaldo Len, Gleice Clemente Souza Russo, Sonia Mayumi Chiba, Vera Lucia Sdepanian, Josefina Aparecida Pellegrini Braga, Maria Stella Figueiredo, Maria Cristina Andrade,et al.
    Elsevier BV

  • Novel Insights into the Pathophysiology and Treatment of Sickle Cell Disease
    Aderson da Silva Araújo, Ana Cristina Silva Pinto, Clarisse Lopes de Castro Lobo, Maria Stella Figueiredo, Sandra Fátima Menosi Gualandro, Sara Teresinha Olalla Saad, and Rodolfo Delfini Cancado
    Informa UK Limited
    Abstract The polymerization of hemoglobin under deoxygenation is the main pathophysiological event in sickle cell diseases, described more than 70 years ago. The last two decades have seen a major increase in knowledge about the cascade of events that follow the polymerization of hemoglobin and the ensuing sickling of red blood cells. Several distinctive therapeutic targets have been discovered as a result, and a few drugs with innovative mechanisms of action are already on the market, while several others are the focus of ongoing trials. The aim of this narrative review is to describe some of the more recent data in the SCD literature regarding pathophysiology and novel treatments.

  • Sickle cell anemia: hierarchical cluster analysis and clinical profile in a cohort in Brazil
    Valéria de Freitas Dutra, Thais Priscila Biassi, and Maria Stella Figueiredo
    Elsevier BV

  • Zinc in sickle cell disease: A narrative review
    Carolinne Thaisa de Oliveira Fernandes Miranda, Karina Marques Vermeulen-Serpa, Ana Carolina Cabañas Pedro, José Brandão-Neto, Sancha Helena de Lima Vale, and Maria Stella Figueiredo
    Elsevier BV

  • miRNA profile and disease severity in patients with sickle cell anemia
    Thaís Priscila Biassi, Elvira Maria Guerra-Shinohara, Patrícia Natália Silva Moretti, Valeria de Freitas Dutra, Ana Carolina Cabañas-Pedro, Grazielle Mecabo, Gisele Wally Braga Colleoni, and Maria Stella Figueiredo
    Springer Science and Business Media LLC

  • Genetic contribution and functional impairment of inflammasome in sickle cell disease
    Valéria de Freitas Dutra, Vinícius Nunes Cordeiro Leal, Fernanda Pereira Fernandes, Cláudia Regina Lustosa Souza, Maria Stella Figueiredo, and Alessandra Pontillo
    Cytokine Elsevier BV

  • Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria
    Rodolfo D. Cançado, Aderson da Silva Araújo, Alex Freire Sandes, Celso Arrais, Clarisse Lopes de Castro Lobo, Maria Stella Figueiredo, Sandra Fátima Menosi Gualandro, Sara Teresinha Olalla Saad, and Fernando Ferreira Costa
    Hematology, Transfusion and Cell Therapy Elsevier BV
    Paroxysmal nocturnal hemoglobinuria is a chronic, multi-systemic, progressive and life-threatening disease characterized by intravascular hemolysis, thrombotic events, serious infections and bone marrow failure. Paroxysmal nocturnal hemoglobinuria results from the expansion of a clone of hematopoietic cells that due to an inactivating mutation of the X-linked gene PIG-A are deficient in glycosylphosphatidylinositol-linked proteins. Early diagnosis, using flow cytometry performed on peripheral blood, the gold standard test to confirm the diagnosis of paroxysmal nocturnal hemoglobinuria, is essential for improved patient management and prognosis. The traditional therapy for paroxysmal nocturnal hemoglobinuria includes blood transfusion, anti-thrombosis prophylaxis or allogeneic bone marrow transplantation. The treatment that has recently become available is the complement blockade by the anti-C5 monoclonal antibody eculizumab. In this consensus, we are aiming to review the diagnosis and treatment of the paroxysmal nocturnal hemoglobinuria patients, as well as the early recognition of its systemic complications. These procedures express the opinions of experts and have been based on the best available evidence and international guidelines, with the purpose of increasing benefits and reducing harm to patients.

  • Serum folate and cytokines in heterozygous β-thalassemia
    Clóvis Paniz, Maylla Rodrigues Lucena, Juliano Felix Bertinato, Magnun Nueldo Nunes Santos, Guilherme Wataru Gomes, Maria Stella Figueiredo, Maria de Fátima Sonati, Vera Lúcia Nascimento Blaia‐D Avila, Ralph Green, and Elvira Maria Guerra‐Shinohara
    International Journal of Laboratory Hematology Wiley

  • Rheumatoid arthritis and sickle cell disease: A potential association
    Suely Roizenblatt, Ana Carolina Cabañas‐Pedro, and Maria Stella Figueiredo
    Wiley
    SM received research funding from Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Juno, Novartis, Pharmacyclics and TG Therapeutics; and received honorarium for advisory board or lecturing for Abbvie, AstraZeneca, BeiGene, Genentech, Gilead, Janssen, Kite and Pharmacyclics. AB received honorarium for lecturing for Bayer, Foundation Medicine and Pfizer. The other authors declare no conflicts of interest.

  • COVID-19 as a trigger of acute chest syndrome in a pregnant woman with sickle cell anemia
    Caio Cesar Justino, Felipe Favorette Campanharo, Marina Nobrega Augusto, Stela Cezarino de Morais, and Maria Stella Figueiredo
    Elsevier BV

  • Daily supplementation with 5 mg of folic acid in Brazilian patients with hereditary spherocytosis
    Clóvis Paniz, Maylla Rodrigues Lucena, Juliano Felix Bertinato, Felipe Rebello Lourenço, Bruna Cipriano A Barros, Guilherme Wataru Gomes, Maria Stella Figueiredo, Rodolfo Delfini Cançado, Vera Lúcia Nascimento Blaia-D Avila, Christine M Pfeiffer,et al.
    SAGE Publications
    Patients with hereditary spherocytosis (HS) have increased rates of erythropoiesis and higher folate requirements. In a case-control study of patients with HS, we evaluated the associations between the use of 5 mg folic acid (FA) daily and serum concentrations of folate, unmetabolized folic acid (UMFA), interleukin (IL)-6, IL-8, IL-10, interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α); and mRNA expression of dihydrofolate reductase ( DHFR), methylene tetrahydrofolate reductase ( MTHFR), IL8, IFNG and TNFA genes. Total serum folate and folate forms were measured in 27 patients with HS (21 users [HS-U] and 6 non-users [HS-NU] of supplemental FA) and 54 healthy controls not consuming 5 mg/day supplemental FA. Each patient was matched to two controls based on age, sex and body mass index. The mononuclear leucocyte mRNA expression of relevant genes and their products were determined. Serum folate, UMFA, 5-methyl-tetrahydrofolate (5-methyl-THF) and tetrahydrofolate (THF) concentrations were significantly higher in HS-U compared with matched healthy controls (p<0.001, n=42). HS-NU had lower serum folate concentrations than matched healthy controls (p=0.044, n=12). HS-U and HS-NU presented similar hematological and biochemical markers profiles. No differences were found between HS-U and HS-NU for cytokine serum concentrations and mRNA expression genes. DHFR mRNA expression was higher in HS-U than in HS-NU. The use of high daily doses of FA for treatment of patients with HS may be excessive and is associated with elevated serum UMFA and elevated DHFR mRNA expression. It is not known whether long-term high-dose FA use by patients with HS might have adverse health effects.

  • Male sickle cell patients, compensated transpubertal hypogonadism and normal final growth
    Paulo Roberto Juliano Martins, Fernanda Bernadelli De Vito, Gláucia Aparecida Domingos Resende, José Kerbauy, Gilberto de Araújo Pereira, Helio Moraes‐Souza, Maria Stella Figueiredo, and Ieda Therezinha Verreschi
    Wiley
    AbstractObjectiveInvestigate the gonadal hormonal function in sickle cell individuals.ContextSickle cell disease (SCD) is associated with delayed physical and sexual development, and it has been related to both primary testicular failure and hypothalamo‐pituitary‐gonadal axis abnormalities.DesignThe study of the pituitary gonadotrophin reserve was done evaluating the hormonal levels before and after stimulation by gonadoliberin.PatientsMale patients with homozygous SCD (18‐39 years, median = 29.5 years).MeasurementsGonadal function was evaluated through clinical parameters and the hormonal quantification.ResultsAlthough low body weight and other clinical signs of undernutrition such as clinical hypoandrogenism and the extreme retardation of puberty were seen in these patients, final stature and hormonal testicular reserve to hCG stimulation were proved to be normal according to our previous data. In the present investigation, the basal luteotropic gonadotropin (LH), follicle‐stimulating hormone (FSH) and testosterone (T) levels were similar between the patients and controls. Prostate‐specific antigen (PSA) levels—used as a biochemical marker of androgenicity, mainly in puberty—were lower in the patients than in the controls and were only correlated with T. A subtle abnormality in the pituitary responsivity to gonadotropin‐releasing hormone (GnRH) was disclosed, with a higher response to LH 60 minutes after stimulation in patients than in controls.ConclusionsThese data, in addition to both the clinical and biochemical signs of hypoandrogenism associated with normal to elevated T levels strongly suggest a peripheral origin of hypogonadism, which is probably due to androgen resistance in the patients with SCD.

  • Molecular matching for patients with haematological diseases expressing altered RHD-RHCE genotypes
    Bruno Ribeiro Cruz, Thamy Caroline de Souza Silva, Bianca de Souza Castro, Akemi Kuroda Chiba, Elyse Moritz, Josefina Pellegrini Braga, Maria Stella Figueiredo, and José O Bordin
    Wiley
    Background and ObjectivesThe high homology and the inverted orientation of RHD and RHCE may give rise to non‐functional and aberrant RH alleles. RH genotyping is used to screen RH matched donors to African descent patients. This study aimed to define a strategy for testing RHD and RHCE variants in blood donors to provide compatible units for transfusion of patients with haematological diseases.Materials and MethodsSamples from 132 patients [101 Sickle cell disease (SCD), 14 myelodysplastic syndrome (MDS), 17 acute myelogenous leukaemia (AML)] and 198 Brazilian donors were studied. Major blood group alleles, RHD, RHCE alleles and RHD zygosity were determined by the blood‐MLPA assay. Sequencing was performed to determine RHD and RHCE variant subtypes. A match was an RH genotype that did not encode Rh antigens absent in the patient, along with matching for ABO, MNS, KEL, FY, JK and DI antigens.ResultsOverall, 7·6% of blood donors and 17.4% of patients presented RH genotypes that predict expression of partial Rh antigens or lack of high prevalence Rh antigens. From 23 patients with clinically relevant RH genotypes, 15 had available matched donors.ConclusionWe report the presence of clinically relevant RH genotypes in SCD and in non‐SCD patients. In our admixed population, many patients carry variant RHCE alleles in heterozygosity with normal RHCE alleles. Thus, our results suggest that donors could be selected based on the normal RH allele.

  • Cerebral Vasoreactivity in Children with Sickle Cell Disease: A Transcranial Doppler Study
    Rejane de Souza Macedo-Campos, Samuel Ademola Adegoke, Maria Stella Figueiredo, Josefina Aparecida Pellegrini Braga, and Gisele Sampaio Silva
    Elsevier BV

  • Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy
    Samuel Ademola Adegoke, Rejane de Souza Macedo-Campos, Josefina Aparecida Pellegrini Braga, Maria Stella Figueiredo, and Gisele Sampaio Silva
    Elsevier BV

  • Quality of life in adults with sickle cell disease: an integrative review of the literature
    Sandra Luzinete Felix de Freitas, Maria Lucia Ivo, Maria Stella Figueiredo, Maria Auxiliadora de Souza Gerk, Cristina Brandt Nunes, and Fernando de Freitas Monteiro
    FapUNIFESP (SciELO)
    ABSTRACT Objective: To identify the available evidence in the literature on health-related quality of life in adults with sickle cell disease. Method: integrative review of MEDLINE, CUMED, LILACS and SciELO databases, from articles developed in this area, published between 2005 and 2015, in English, Portuguese or Spanish. Results: 22 articles were included, six scales were used to evaluate health-related quality of life scores: three generic and three specific. No specific scale for adults with sickle cell disease has been adapted to Brazilian Portuguese so far. Patients affected by frequent painful crises, with low adherence to treatment, had a compromised quality of life. Conclusion: Selected studies have shown that patients with sickle cell disease have worse scores than the general population. These indicators should be instrumental to the nurse in the proposal of interventions and strategies of assistance and socio-educational, with a view to improving the quality of life of this clientele.

  • Impact of Hydroxyurea on Anthropometry and Serum 25-Hydroxyvitamin D among Children with Sickle Cell Disease
    Samuel A. Adegoke, Josefina A.P. Braga, Adekunle D. Adekile, and Maria S. Figueiredo
    Ovid Technologies (Wolters Kluwer Health)
    Objective: To evaluate the impact of hydroxyurea (HU) on nutritional status and serum 25-hydroxyvitamin D (25-OHD) of children with sickle cell disease (SCD). Design: Anthropometry and serum 25-OHD were determined in 98 children with SCD, comprising of 68 in HU-group and 30 in HU-naive group. Results: Underweight was more common among HU-naive group (33.3% vs. 10.3%, P=0.009), while 79.4% of HU-group against 56.7% HU-naive had normal body mass index percentile for age and sex, P=0.028. None of the HU-group compared with 13.3% of the HU-naive had severe vitamin D deficiency, P=0.002. The mean 25-OHD of the HU-group was also higher (24.1±1.2 vs. 19.1±9.8 ng/mL, P=0.007). Conclusions: HU possibly ameliorate growth retardation and vitamin D deficiency in children with SCD.

  • The Association of Serum 25-Hydroxyvitamin D with Biomarkers of Hemolysis in Pediatric Patients with Sickle Cell Disease
    Samuel A. Adegoke, Josefina A.P. Braga, Adekunle D. Adekile, and Maria S. Figueiredo
    Ovid Technologies (Wolters Kluwer Health)
    Although vitamin D deficiency (VDD) has been linked to anemia among sickle cell disease (SCD), its relationship with hemolysis is unclear. Serum 25-hydroxyvitamin D and biomarkers of hemolysis (hemoglobin [Hb]/hematocrit, reticulocyte percentage, absolute reticulocyte, and lactate dehydrogenase [LDH] levels) in 36 hydroxyurea-naive SCD children were quantified. Correlations were significantly positive with Hb/hematocrit (r=0.40, P=0.017; r=0.45, P=0.006, respectively); inverse with reticulocyte percentage, absolute reticulocyte, and LDH (r=−0.44, P=0.008; r=−0.47, P=0.007; r=−0.45, P=0.007, respectively). In VDD groups, Hb was lower (P=0.014), reticulocyte counts and LDH were higher (P=0.047 and 0.003, respectively). Serum 25-hydroxyvitamin D correlated with biomarkers of hemolysis in SCD and VDD may play a role in SCD pathogenesis.

RECENT SCHOLAR PUBLICATIONS

  • COVID-19 as a trigger of acute chest syndrome in a pregnant woman with sickle cell anemia
    CC Justino, FF Campanharo, MN Augusto, SC Morais, MS Figueiredo
    Hematology, transfusion and cell therapy 42 (3), 212-214 2020

  • A daily dose of 5 mg folic acid for 90 days is associated with increased serum unmetabolized folic acid and reduced natural killer cell cytotoxicity in healthy Brazilian adults
    C Paniz, JF Bertinato, MR Lucena, E De Carli, PM da Silva Amorim, ...
    The Journal of nutrition 147 (9), 1677-1685 2017

  • Relationship between serum 25-hydroxyvitamin D and inflammatory cytokines in paediatric sickle cell disease
    SA Adegoke, OS Smith, AD Adekile, MS Figueiredo
    Cytokine 96, 87-93 2017

  • A comprehensive, ethnically diverse library of sickle cell disease-specific induced pluripotent stem cells
    S Park, A Gianotti-Sommer, FJ Molina-Estevez, K Vanuytsel, N Skvir, ...
    Stem Cell Reports 8 (4), 1076-1085 2017

  • The compound state: Hb S/beta-thalassemia
    MS Figueiredo
    Revista brasileira de hematologia e hemoterapia 37 (3), 150-152 2015

  • Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients
    PCJL Santos, RD Canado, AC Pereira, IT Schettert, RAG Soares, ...
    Blood Cells, Molecules, and Diseases 46 (4), 302-307 2011

  • Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease: correlation with transcranial Doppler findings
    GS Silva, P Vicari, MS Figueiredo, H Carrete, MH Idagawa, AR Massaro
    Stroke 40 (7), 2408-2412 2009

  • Clinical, hematological, and molecular characterization of sickle cell anemia pediatric patients from two different cities in Brazil
    IM Lyra, MS Gonalves, JAP Braga, MF Gesteira, MH Carvalho, ...
    Cadernos de saude publica 21, 1287-1290 2005

  • Renal dysfunction in patients with sickle cell anemia or sickle cell trait
    R Sesso, MA Almeida, MS Figueiredo, JO Bordin
    Brazilian journal of medical and biological research 31, 1257-1262 1998

  • Effect of α‐thalassemia and β‐globin gene cluster haplotypes on the hematological and clinical features of sickle‐cell anemia in Brazil
    MS Figueiredo, J Kerbauy, MS Gonalves, VR Arruda, STO Saad, ...
    American journal of hematology 53 (2), 72-76 1996

MOST CITED SCHOLAR PUBLICATIONS

  • Effect of α‐thalassemia and β‐globin gene cluster haplotypes on the hematological and clinical features of sickle‐cell anemia in Brazil
    MS Figueiredo, J Kerbauy, MS Gonalves, VR Arruda, STO Saad, ...
    American journal of hematology 53 (2), 72-76 1996
    Citations: 120

  • A daily dose of 5 mg folic acid for 90 days is associated with increased serum unmetabolized folic acid and reduced natural killer cell cytotoxicity in healthy Brazilian adults
    C Paniz, JF Bertinato, MR Lucena, E De Carli, PM da Silva Amorim, ...
    The Journal of nutrition 147 (9), 1677-1685 2017
    Citations: 81

  • Clinical, hematological, and molecular characterization of sickle cell anemia pediatric patients from two different cities in Brazil
    IM Lyra, MS Gonalves, JAP Braga, MF Gesteira, MH Carvalho, ...
    Cadernos de saude publica 21, 1287-1290 2005
    Citations: 79

  • Renal dysfunction in patients with sickle cell anemia or sickle cell trait
    R Sesso, MA Almeida, MS Figueiredo, JO Bordin
    Brazilian journal of medical and biological research 31, 1257-1262 1998
    Citations: 77

  • Hereditary hemochromatosis: mutations in genes involved in iron homeostasis in Brazilian patients
    PCJL Santos, RD Canado, AC Pereira, IT Schettert, RAG Soares, ...
    Blood Cells, Molecules, and Diseases 46 (4), 302-307 2011
    Citations: 69

  • Brain magnetic resonance imaging abnormalities in adult patients with sickle cell disease: correlation with transcranial Doppler findings
    GS Silva, P Vicari, MS Figueiredo, H Carrete, MH Idagawa, AR Massaro
    Stroke 40 (7), 2408-2412 2009
    Citations: 64

  • Relationship between serum 25-hydroxyvitamin D and inflammatory cytokines in paediatric sickle cell disease
    SA Adegoke, OS Smith, AD Adekile, MS Figueiredo
    Cytokine 96, 87-93 2017
    Citations: 55

  • A comprehensive, ethnically diverse library of sickle cell disease-specific induced pluripotent stem cells
    S Park, A Gianotti-Sommer, FJ Molina-Estevez, K Vanuytsel, N Skvir, ...
    Stem Cell Reports 8 (4), 1076-1085 2017
    Citations: 46

  • The compound state: Hb S/beta-thalassemia
    MS Figueiredo
    Revista brasileira de hematologia e hemoterapia 37 (3), 150-152 2015
    Citations: 44

  • COVID-19 as a trigger of acute chest syndrome in a pregnant woman with sickle cell anemia
    CC Justino, FF Campanharo, MN Augusto, SC Morais, MS Figueiredo
    Hematology, transfusion and cell therapy 42 (3), 212-214 2020
    Citations: 29